Bendamustine

Generic Name
Bendamustine
Brand Names
Belrapzo, Bendeka, Treanda, Vivimusta
Drug Type
Small Molecule
Chemical Formula
C16H21Cl2N3O2
CAS Number
16506-27-7
Unique Ingredient Identifier
9266D9P3PQ
Background

Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...

Indication

Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions
Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
Associated Therapies
-

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

First Posted Date
2010-01-15
Last Posted Date
2020-02-11
Lead Sponsor
Mayo Clinic
Target Recruit Count
70
Registration Number
NCT01049945
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

and more 2 locations

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

First Posted Date
2010-01-05
Last Posted Date
2017-07-31
Lead Sponsor
Robert Redner, MD
Target Recruit Count
29
Registration Number
NCT01042704
Locations
🇺🇸

UPMC Cancer Centers - Arnold Palmer at Mountain View, Greensburg, Pennsylvania, United States

🇺🇸

UPMC Cancer Centers - Arnold Palmer at Oakbrook, Greensburg, Pennsylvania, United States

🇺🇸

Hematology/Oncology - Private Practice, McKeesport, Pennsylvania, United States

and more 19 locations

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

Phase 2
Completed
Conditions
Interventions
First Posted Date
2009-12-10
Last Posted Date
2016-08-19
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
55
Registration Number
NCT01029730
Locations
🇺🇸

Florida Cancer Specialists, Ft. Myers, Florida, United States

🇺🇸

Hematology Oncology of the North Shore, Skokie, Illinois, United States

🇺🇸

Holy Cross Hospital, Ft. Lauderdale, Florida, United States

and more 17 locations

Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine

Early Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-12-01
Last Posted Date
2017-01-10
Lead Sponsor
University of Kansas Medical Center
Target Recruit Count
17
Registration Number
NCT01022021
Locations
🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

First Posted Date
2009-10-07
Last Posted Date
2024-08-22
Lead Sponsor
University of Giessen
Target Recruit Count
549
Registration Number
NCT00991211
Locations
🇩🇪

StiL Head Office; Justus-Liebig-University, Giessen, Germany

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

First Posted Date
2009-10-01
Last Posted Date
2019-05-15
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
49
Registration Number
NCT00987493
Locations
🇨🇭

Inselspital Bern, Bern, Switzerland

🇨🇭

Stadtspital Triemli, Zürich, Switzerland

🇨🇭

Kantonsspital Baden, Baden, Switzerland

and more 13 locations

Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2009-09-25
Last Posted Date
2014-03-12
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
50
Registration Number
NCT00984542
Locations
🇺🇸

Hardin Memorial Hosptial, Elizabethtown, Kentucky, United States

🇺🇸

Jackson-Madison County Hospital, Jackson, Tennessee, United States

🇺🇸

Baptist Regional Cancer Center at Baptist Riverside, Knoxville, Tennessee, United States

and more 3 locations

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

First Posted Date
2009-09-10
Last Posted Date
2019-12-02
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
34
Registration Number
NCT00974233
Locations
🇺🇸

Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States

🇺🇸

Gundersen Clinic, La Crosse, Wisconsin, United States

🇺🇸

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

and more 7 locations

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma

Phase 2
Completed
Conditions
Interventions
First Posted Date
2009-08-17
Last Posted Date
2013-02-12
Lead Sponsor
French Innovative Leukemia Organisation
Target Recruit Count
45
Registration Number
NCT00959686
Locations
🇫🇷

Dr Gandhi DAMAJ, Amiens, France

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)

First Posted Date
2009-08-04
Last Posted Date
2022-03-03
Lead Sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie
Target Recruit Count
20
Registration Number
NCT00951457
Locations
🇦🇹

Krankenhaus der Stadt Linz, Linz, Austria

🇦🇹

Universitaetsklinik f. Innere Medizin III, Salzburg, Austria

🇦🇹

A.ö. Landeskrankenhaus Leoben, Leoben, Austria

and more 4 locations
© Copyright 2024. All Rights Reserved by MedPath